15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Cognition Therapeutics Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $4.00 to $4.00, so the covering firms are broadly aligned. The average target of $4.00 sits 333% above the current $0.92. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.07 next quarter toward $-0.28 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Cognition Therapeutics Inc.
As of Jul, 3 of 3 firms rate CGTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CGTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.07
Range $-0.08 – $-0.07 · 4 analysts · +21% YoY
Next period, 4 analysts expect Cognition Therapeutics Inc to earn $-0.07 a share (range $-0.08 – $-0.07), versus $-0.06 a year earlier. Full-year consensus is $-0.32, growing to $-0.28 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Cognition Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CGTX.
#1
Daniil Gataulin
Chardan Capital · Rank #36
Buy
$4.00+332.9% to target
Overall win rate
55%
+ Follow
#2
WW
William Wood
B. Riley Securities
Buy
$3.00+224.7% to target
Coverage
—
+ Follow
CGTX stock forecast FAQ
What is CGTX's average 12-month price target?+
The 1 analysts with a live target average $4.00 for Cognition Therapeutics Inc over the next 12 months, ranging from a $4.00 high to a $4.00 low.
Is CGTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover CGTX?+
3 analysts have an active rating on Cognition Therapeutics Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering CGTX?+
Among analysts who currently cover CGTX, Daniil Gataulin of Chardan Capital has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $4.00 target.
What is Cognition Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.07 per share (range $-0.08 – $-0.07) across 4 analysts. Full-year EPS is projected at $-0.32, rising to $-0.28 the following year.
How much revenue is Cognition Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading CGTX lately?+
As of Jul, 3 of 3 firms rate CGTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CGTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
